Clearbridge Investments LLC Sells 1,991,131 Shares of Definitive Healthcare Corp. (NASDAQ:DH)

Clearbridge Investments LLC cut its stake in shares of Definitive Healthcare Corp. (NASDAQ:DH) by 88.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 266,719 shares of the company’s stock after selling 1,991,131 shares during the quarter. Clearbridge Investments LLC owned 0.23% of Definitive Healthcare worth $2,152,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in DH. Tower Research Capital LLC TRC boosted its position in Definitive Healthcare by 599.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,786 shares of the company’s stock worth $58,000 after buying an additional 4,959 shares during the period. Norden Group LLC acquired a new position in shares of Definitive Healthcare in the 1st quarter worth approximately $83,000. Berry Wealth Group LP acquired a new position in shares of Definitive Healthcare in the 1st quarter worth approximately $99,000. Susquehanna Fundamental Investments LLC acquired a new position in shares of Definitive Healthcare in the 1st quarter worth approximately $120,000. Finally, Reynders McVeigh Capital Management LLC acquired a new position in shares of Definitive Healthcare in the 4th quarter worth approximately $129,000. 98.67% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on DH. William Blair restated an “outperform” rating on shares of Definitive Healthcare in a research report on Tuesday, May 14th. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Definitive Healthcare from $10.00 to $7.00 and set a “hold” rating on the stock in a research report on Thursday, May 9th. Needham & Company LLC reiterated a “hold” rating on shares of Definitive Healthcare in a research report on Wednesday, May 8th. Stifel Nicolaus dropped their target price on shares of Definitive Healthcare from $11.00 to $9.50 and set a “buy” rating on the stock in a research report on Wednesday, May 8th. Finally, Canaccord Genuity Group decreased their price target on shares of Definitive Healthcare from $10.00 to $8.00 and set a “hold” rating for the company in a research note on Wednesday, May 8th. Eight equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $9.56.

Definitive Healthcare Trading Up 1.9 %

NASDAQ:DH traded up $0.11 on Thursday, reaching $5.95. 8,666 shares of the company’s stock were exchanged, compared to its average volume of 691,082. The company has a debt-to-equity ratio of 0.20, a current ratio of 2.30 and a quick ratio of 2.30. Definitive Healthcare Corp. has a 52 week low of $4.38 and a 52 week high of $12.37. The stock has a fifty day simple moving average of $5.52 and a 200-day simple moving average of $7.25.

Definitive Healthcare (NASDAQ:DH) last issued its earnings results on Tuesday, May 7th. The company reported ($0.02) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.04). The business had revenue of $63.48 million for the quarter, compared to the consensus estimate of $64.00 million. Definitive Healthcare had a positive return on equity of 0.51% and a negative net margin of 78.16%. On average, analysts anticipate that Definitive Healthcare Corp. will post 0.1 earnings per share for the current fiscal year.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.